FindTrial
Sign In

A PHASE II STUDY OF VELCADE BORTEZOMIB - PS341 IN THE TREATMENT OF PATIENTS OVER 18 YEARS WITH Ph LEUKEMIA

A PHASE II STUDY OF VELCADE BORTEZOMIB - PS341 IN THE TREATMENT OF PATIENTS OVER 18 YEARS WITH Ph LEUKEMIA

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-002977-22-IT
Enrollment
Unknown
Registered
2007-02-14
Start date
2004-09-28
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients over 18 years with Ph leukaemia MedDRA version: 9.1 Level: LLT Classification code 10009013 Term: Chronic myeloid leukaemia

Interventions

Trade Name: VELCADE Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Bortezomib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.5-

Sponsors

AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026